Welcome to our library! Here you will find IDB publications on Health Technology Assessment (HTA), Health Benefit Plans (HBP), pharmaceutical policy, drugs and medical devices regulation, catastrophic funds, and horizon scanning, among others. We classify our publications into three categories: books, policy documents, and technical notes.
This policy brief is based on a webinar presented by Luis Alejandro Rivera, Chief of the Pricing Unit at the Dirección Nacional de Medicamentos (National Directorate of Medicines DNM) in El Salvador. The presentation was given on July 2019. Rising prices of medications are a global concern as healthcare expenditures soar and more patients are unable to access the medicines they need. El Salvador has managed to control and lower the price of prescription medicines for both innovator and generic medicines, while maintaining a well-functioning and cost-saving pharmaceutical market. This publication presents takeaways, such as price setting methods, the identification of appropriate market segments, and the introduction of online monitoring platforms, so that other policymakers may use them when introducing price regulation in their own pharmaceutical markets.
This technical note discusses the application of economic evidence in health technology assessments for decision-making on the allocation of health resources. There is already recognition in Latin America that the economic dimensions of health interventions, such as cost-effectiveness and budgetary impact, are critical dimensions that should always be considered when making decisions about the coverage or inclusion of technologies in benefits packages. However, there are still barriers and constraints that prevent the evaluation of economic evidence in the region from being an integral part of all decision- making processes, with serious implications for the equity and efficiency with which health resources are allocated. The purpose of this technical note is to provide elements and tools that contribute, in a practical way, to overcoming these barriers, answering the questions asked by health systems that are beginning to apply economic evidence in their evaluation and decision-making processes. How do we know if a technology or intervention is cost- effective in our context? What cost-effectiveness threshold should be applied? How might non-economic criteria and dimensions influence our cost-effectiveness threshold? What limit should be considered when a technology implies a high budgetary impact in a particular health system? Given the existing difficulties in generating local economic evidence, what can the economic evidence generated in other jurisdictions tell us? How can economic evidence be taken into account in a fragmented health system? Consideration of these aspects is key to ensuring fairer, more transparent allocation of health resources and thus achieving more efficient and equitable health systems in Latin America.
THE “CANCER INDUSTRY” AND THE PHARMACEUTICAL POLICY IN GERMANY. PRESENTACIÓN DE DR. KARL LAUTERBACH. ENERO 2016
VALUE BASED DRUG REIMBURSEMENT: INTRODUCTION TO THE MAIN FEATURES OF THE GERMAN PHARMACEUTICAL POLICY. PRESENTACIÓN DE DR. WOLFGANG GREINER. SEPTIEMBRE 2015
NPS MEDICINEWISE: IMPROVING MEDICINE AND MEDICAL TEST USE IN AUSTRALIA. PRESENTACIÓN DE AINE HEANEY AND JONATHAN DARTNELL. AUGUST 2015
EXPLICIT PRIORITY SETTING IN NEW ZEALAND AND THE UK. PRESENTACIÓN DE TOMMY WILKINSON. ABRIL 2014
HEALTH BENEFITS PLANS IN OECD COUNTRIES. PRESENTACIÓN DE VALÉRIE PARIS. MAYO DE 2014
Guaranteeing the right to health care under equal conditions for all is a goal that every society desires to achieve, particularly in a region as unequal as Latin America and the Caribbean. Universal coverage is an important objective for most countries; however, the context for attaining universal coverage is difficult, as the pressure on health spending mounts with each passing day. So, what to leave in or out of a health benefit plan?